These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34858068)

  • 1. Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment.
    Gandi C; Sacco E
    Clin Pharmacol; 2021; 13():209-223. PubMed ID: 34858068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.
    De Nunzio C; Brucker B; Bschleipfer T; Cornu JN; Drake MJ; Fusco F; Gravas S; Oelke M; Peyronnet B; Tutolo M; van Koeveringe G; Madersbacher S
    Eur Urol; 2021 Apr; 79(4):492-504. PubMed ID: 33402296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing urinary incontinence in women - a review of new and emerging pharmacotherapy.
    Bientinesi R; Sacco E
    Expert Opin Pharmacother; 2018 Dec; 19(18):1989-1997. PubMed ID: 30304645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel.
    Farag F; Sakalis VI; Arteaga SM; Sihra N; Karavitakis M; Arlandis S; Bø K; Cobussen-Boekhorst H; Costantini E; de Heide M; Groen J; Peyronnet B; Phé V; van Poelgeest-Pomfret ML; van den Bos TWL; van der Vaart H; Harding CK; Carmela Lapitan M; Imran Omar M; Nambiar AK
    Eur Urol; 2023 Sep; 84(3):302-312. PubMed ID: 37331921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
    Rechberger T; Kulik-Rechberger B; Miotła P; Wróbel A
    Ginekol Pol; 2014 Mar; 85(3):214-9. PubMed ID: 24783434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future pharmacotherapy for treating overactive bladder.
    Thiagamoorthy G; Cardozo L; Robinson D
    Expert Opin Pharmacother; 2016 Jul; 17(10):1317-25. PubMed ID: 27253972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
    Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
    Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for overactive bladder.
    Karmarkar R; Khullar V
    Expert Opin Emerg Drugs; 2015; 20(4):613-24. PubMed ID: 26359223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current optimal pharmacologic therapies for overactive bladder.
    Jiang YH; Kuo HC
    Expert Opin Pharmacother; 2023; 24(18):2005-2019. PubMed ID: 37752121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.
    Kitta T; Chiba H; Kon M; Higuchi M; Kusakabe N; Ouchi M; Togo M; Abe-Takahashi Y; Tsukiyama M; Shinohara N
    J Pediatr Urol; 2022 Oct; 18(5):563-569. PubMed ID: 35965225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence.
    Andersson KE; Chapple CR; Cardozo L; Cruz F; Hashim H; Michel MC; Tannenbaum C; Wein AJ
    Curr Opin Urol; 2009 Jul; 19(4):380-94. PubMed ID: 19448545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
    Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D; Thiagamoorthy G; Cardozo L
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary incontinence in men: current and developing therapy options.
    Burden H; Abrams P
    Expert Opin Pharmacother; 2016; 17(5):715-26. PubMed ID: 26800277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower Urinary Tract Symptoms: What's New in Medical Treatment?
    Peyronnet B; Brucker BM; Michel MC
    Eur Urol Focus; 2018 Jan; 4(1):17-24. PubMed ID: 29665997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life.
    Jayarajan J; Radomski SB
    Res Rep Urol; 2013 Dec; 6():1-16. PubMed ID: 24400248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
    Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
    J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder.
    Lambregts AP; Nieuwhof-Leppink AJ; Klijn AJ; Schroeder RPJ
    J Pediatr Urol; 2022 Jun; 18(3):351.e1-351.e8. PubMed ID: 35283021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.